China’s Hua Medicine plans to list in Hong Kong to raise money for the development of its diabetes treatment. One story has found that some 47 per cent of the Chinese adult population was estimated to have either diabetes or prediabetes. Photo: Alamy

Chinese diabetes drug maker Hua Medicine is second firm to seek Hong Kong IPO under new rules

Company aims to raise some US$200 million to develop drug to lower blood glucose levels

Topic |   IPO

TOP PICKS

China’s Hua Medicine plans to list in Hong Kong to raise money for the development of its diabetes treatment. One story has found that some 47 per cent of the Chinese adult population was estimated to have either diabetes or prediabetes. Photo: Alamy
READ FULL ARTICLE
Eric Ng

Eric Ng

Eric joined the SCMP in 1998 after brief stints in a trading company and translation and editing roles at Dow Jones and Edinburgh Financial Publishing. He has close to 20 years of experience covering China's energy, mining and industrial materials sectors, and has recently added biotechnology to his coverage. Eric has a Masters of Business Administration degree.